CAPR

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy (DMD). The company also utilizes its proprietary StealthX™ platform to create precision-engineered exosomes aimed at targeted delivery of therapeutics, including oligonucleotides and proteins, to treat a variety of diseases. Capricor collaborates with academic institutions to support its research and development efforts.